Items Tagged ‘obinutuzumab’

December 15th, 2016

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma

By

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH). Follicular lymphoma […]

View full entry

Tags: ASH 2016, B-cells, FL, Follicular Lymphoma, GALLIUM trial, Gazyva, News, Non-Hodgkin's Lymphoma, obinutuzumab, rituxan, rituxumab


January 15th, 2015

FDA Approves Gazyva® (Obinutuzumab) Supplemental Biologics License Application with New Data in Previously Untreated Chronic Lymphocytic Leukemia

By

Genentech announced that the U.S. Food and Drug Administration (FDA) approved a supplemental biologics license application (sBLA) for Gazyva in combination with chlorambucil chemotherapy in people with previously untreated chronic lymphocytic leukemia (CLL). Gazyva was the first medicine approved with the FDA’s Breakthrough Therapy Designation, and was approved for use in combination with chlorambucil in […]

View full entry

Tags: Chronic Lymphocytic Leukemia, CLL, gayza, Leukemia, News, obinutuzumab